Innovent Biologics (01801: HK), a leading China-based biopharmaceutical company, posted strong interim results for the six months ended 30 June 2026, underpinned by robust product sales, disciplined cost control and expanding global partnerships.
Financial Performance • Total revenue rose 44.8 % year-on-year (YoY) to RMB 8.62 billion, driven by a 56.7 % jump in product revenue to RMB 8.20 billion. • Gross profit increased 43.0 % to RMB 7.32 billion; gross margin slipped slightly to 85.0 % (1H25: 86.0 %). • IFRS net profit advanced 50.2 % to RMB 1.25 billion, while non-IFRS net profit reached RMB 1.70 billion, up 40.5 %. • Non-IFRS EBITDA climbed 47.1 % to RMB 2.08 billion. • R&D spending expanded to RMB 1.68 billion, reflecting intensified late-stage and global study activity; R&D represented roughly 19 % of total revenue. • Selling and marketing outlays grew to RMB 3.24 billion, but the ratio to product revenue improved to 39.5 % (1H25: 45.4 %). • Cash and short-term investments stood at RMB 30.20 billion (US$4.5 billion) as of 31 July 2026, providing ample liquidity for strategic initiatives.
Commercial Franchise • Portfolio now totals 20 marketed products, 13 of which are listed on China’s National Reimbursement Drug List. • New approvals/expansions in 1H26 include Verzenios (abemaciclib), Vanflyta (quizartinib) and the tenth indication for flagship PD-1 antibody Tyvyt (sintilimab). • General biomedicine franchise gained traction from mazdutide (GCG/GLP-1 dual agonist), SINTBILO (tafolecimab), SYCUME (teprotumumab) and PECONDLE (picankibart).
Pipeline and Globalization • Three high-potential assets progressed to, or near, global Phase 3 trials—IBI363 (PD-1/IL-2α-biased immuno-cytokine), arcotatug tavatecan (CLDN18.2 ADC, IBI343/TAK-921) and IBI324 (VEGF/ANG2 bispecific for retinal diseases)—collectively targeting markets exceeding US$60 billion. • Ongoing registrational studies include IBI354 (HER2 ADC) in ovarian and breast cancers and IBI3003 (GPRC5D/BCMA/CD3 tri-specific antibody) in multiple myeloma. • Early-stage pipeline features more than a dozen ADCs, multi-specific antibodies, small-molecule and siRNA programs across oncology, metabolic, cardiovascular, autoimmune and ophthalmology indications.
Strategic Alliances • Recent multi-asset deals with Takeda, Pfizer and Eli Lilly carry potential aggregate milestones of roughly US$34 billion and five co-development/co-commercialization programmes. • Additional collaborations with Daiichi Sankyo and Spero Therapeutics enhance oncology and autoimmune portfolios.
Operational Capabilities & ESG • Suzhou manufacturing campus now operates 140,000-litre bioreactor capacity and secured EMA GMP certification in 1H26. • Innovent remains the sole China biotech with MSCI ESG ‘AAA’ status and is included in the Hang Seng Index, HSCEI and Hang Seng ESG Enhanced Index.
Outlook Management highlights a “new stage of high-quality growth,” supported by a maturing commercial base, an advancing global pipeline and reinforced balance sheet, positioning Innovent Biologics to pursue its ambition of becoming a global premier biopharmaceutical company.
Comments